TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F21%3A00013231" target="_blank" >RIV/00023736:_____/21:00013231 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/21:10425780 RIV/00216208:11140/21:10425780 RIV/00216208:11110/21:10425780 RIV/00064203:_____/21:10425780 RIV/00216208:11130/21:10425780

Výsledek na webu

<a href="https://doi.org/10.1080/2162402X.2021.1889822" target="_blank" >https://doi.org/10.1080/2162402X.2021.1889822</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/2162402X.2021.1889822" target="_blank" >10.1080/2162402X.2021.1889822</a>

Jazyk výsledku

angličtina

Název v původním jazyce

TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients

Popis výsledku v původním jazyce

Accumulating evidence indicates that immune checkpoint inhibitors (ICIs) can restore CD8+ cytotoxic T lymphocyte (CTL) functions in preclinical models of acute myeloid leukemia (AML). However, ICIs targeting programmed cell death 1 (PDCD1, best known as PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4) have limited clinical efficacy in patients with AML. Natural killer (NK) cells are central players in AML-targeting immune responses. However, little is known on the relationship between co-inhibitory receptors expressed by NK cells and the ability of the latter to control AML. Here, we show that hepatitis A virus cellular receptor 2 (HAVCR2, best known as TIM-3) is highly expressed by NK cells from AML patients, correlating with improved functional licensing and superior effector functions. Altogether, our data indicate that NK cell frequency as well as TIM-3 expression levels constitute prognostically relevant biomarkers of active immunity against AML.

Název v anglickém jazyce

TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients

Popis výsledku anglicky

Accumulating evidence indicates that immune checkpoint inhibitors (ICIs) can restore CD8+ cytotoxic T lymphocyte (CTL) functions in preclinical models of acute myeloid leukemia (AML). However, ICIs targeting programmed cell death 1 (PDCD1, best known as PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4) have limited clinical efficacy in patients with AML. Natural killer (NK) cells are central players in AML-targeting immune responses. However, little is known on the relationship between co-inhibitory receptors expressed by NK cells and the ability of the latter to control AML. Here, we show that hepatitis A virus cellular receptor 2 (HAVCR2, best known as TIM-3) is highly expressed by NK cells from AML patients, correlating with improved functional licensing and superior effector functions. Altogether, our data indicate that NK cell frequency as well as TIM-3 expression levels constitute prognostically relevant biomarkers of active immunity against AML.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

<a href="/cs/project/NV18-03-00277" target="_blank" >NV18-03-00277: Míra polymorfizmů v NK receptorech a jejich ligandech v rámci české populace</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

OncoImmunology

ISSN

2162-4011

e-ISSN

—

Svazek periodika

10

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

"art. no. e1889822"

Kód UT WoS článku

000627790900001

EID výsledku v databázi Scopus

2-s2.0-85102181179